Effectiveness of early dipyrone administration on severity of dengue virus infection in a prospective cohort;Efecto de la administración temprana de dipirona sobre la gravedad del dengue en una cohorte prospectiva

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 23, Issue 10, 2005, Pages 593-597

  Díaz Quijano, Fredi Alexander ^a   Villar Centeno, Luis Ángel ^a   Martínez Vega, Ruth Aralí ^a  

^a UNIVERSIDAD INDUSTRIAL DE SANTANDER   (Colombia)

Author keywords

Dengue; Dipyrone; Prospective cohort

Indexed keywords

DIPYRONE; IMMUNOGLOBULIN M;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DEMOGRAPHY; DENGUE; DENGUE VIRUS; DISEASE SEVERITY; DRUG EFFICACY; EARLY INTERVENTION; EVALUATION; FEMALE; HEMATOCRIT; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PROSPECTIVE STUDY; RISK; SAMPLE; STATISTICAL SIGNIFICANCE; SYMPTOM; THROMBOCYTE COUNT; TITRIMETRY; VIRUS ISOLATION;

EID: 29444458550     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13081567     Document Type: Article

References (18)

1. Kautner I, Robinson MJ, Kuhnle U. Dengue virus infection: Epidemiology, pathogenesis, clinical presentation, diagnosis, and prevention. J Pediatr. 1997;131:516-24.
2. Halstead SB. The XXth century dengue pandemic: need for surveillance and research. World Health Stat Q. 1992;45:292-8.
3. SIVIGILA. Boletín Epidemiológico Semanal. Semana epidemiológica No. 26. Junio 22-28 de 2003. Disponible en: www.col.ops-oms.org/sivigila/2003/BOLE26_03.pdf
4. Guzmán MG, Kouri GP, Bravo J, Soler M, Vázquez S, Morier L. Dengue hemorrhagic fever in Cuba, 1981: A Retrospective Seroepidemiologic Study. Am J Trop Med Hyg. 1990;42:179-84.
5. Organización Panamericana de la Salud. Dengue y Dengue Hemorrágico en las Américas: Guías para su prevención y control. Washington: Publicación Científica 548; 1995. p. 110.
6. Rigau-Pérez JG, Clark GG, Gubler DJ, Reiter P, Sanders EJ, Vorndam AV. Dengue and dengue haemorrhagic fever. Lancet. 1998;352:971-7.
7. Hedenmalm K, Spigset O. Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole). Eur J Clin Pharmacol. 2002;58:265-74.
8. Backstrom M, Hagg S, Mjorndal T, Dahlqvist R. Utilization pattern of metamizole in northern Sweden and risk estimates of agranulocytosis. Pharmacoepidemiol Drug Saf. 2002;11:239-45.
9. Van der Klauw MM, Goudsmit R, Halie MR, Van't Veer MB, Herings RM, Wilson JH, et al. A population-based case-cohort study of drug-associated agranulocytosis. Arch Intern Med. 1999;159:369-74.
10. Van der Klauw MM, Wilson JH, Stricker BH. Drug-associated agranulocytosis: 20 years of reporting in The Netherlands (1974-1994). Am J Hematol. 1998;57:206-11.
11. Bensenor IM. To use or not to use dipyrone? Or maybe, Central Station versus ER? That is the question. Sao Paulo Med J. 2001;119:190-1.
12. Organización Panamericana de la Salud. Definiciones de Casos. Dengue. Boletín Epidemiológico. 2000;21:14-5.
13. Lei HY, Yeh TM, Liu HS, Lin YS, Chen SH, Liu CC. Immunopathogenesis of dengue virus infection. J Biomed Sci. 2001;8:377-88.
14. La Russa VF, Innis BL. Mechanisms of dengue virus-induced bone marrow suppression. Baillières Clin Haematol. 1995;8:249-70.
15. Lin CF, Lei HY, Liu CC, Liu HS, Yeh TM, Wang ST, et al. Generation of IgM anti-platelet autoantibody in dengue patients. J Med Virol. 2001;63:143-9.
16. Conti L, Fidani P, Chistolini A, Francesconi M, Gandolfo GM, Mazzucconi MG. Detection of drug-dependent IgG antibodies with antiplatelet activity by the antiglobulin consumption assay. Haemostasis. 1984;14:480-6.
17. Andrade SE, Martínez C, Walker AM. Comparative safety evaluation of non-narcotic analgesics. J Clin Epidemiol. 1998;51:1357-65.
18. Maj S, Lis Y. The incidence of metamizole sodium-induced agranulocytosis in Poland. J Int Med Res. 2002;30:488-95.